Chello 2006

1 Treatments

Studied treatment atorvastatin 20mg daily

Control treatment placebo

Concomittant treatments -

Age (yr) 65 y

2 Patients

Patients patients with scheduled coronary bypass surgery

Inclusion criteria -

Exclusion criteria -

Hypertension (%) 45%

Diabetes (%) -

CAD (%) 100%

LVEF (%) -

beta-blocker use (%) 7%

ACEI (%) -

3 Methods

Blinding double-blind

Design Parallel groups

Centers -

Geographical area -

Sizes 20/20

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>AF</td>
<td>2/20</td>
<td>5/20</td>
<td>0,40</td>
<td>[0,07; 2,37]</td>
</tr>
</tbody>
</table>
5 References
Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit 
Care Med 2006;34:660-7 [16505650] 10.1097/01.CCM.0000201407.89977.EA